Nanoformulations in Cancer: Focus on Patents and Clinical Trials

Abstract

The transformation of a normal cell state to malignant cell is a multifactorial process, as cancer is a complex network of diseases. There are various types of cancer, each with its own underlying mechanisms and symptoms. The rise in modernization has significantly limited the mobility and has also altered the diets, leading to an increased rate of cancer mortality worldwide. The treatment options in cancer therapy, such as chemotherapy and radiotherapy, result in compromising the well-being of patients with cancer. Nanoformulation has emerged as convincing tools in cancer drug delivery. In order to gather pertinent information on Nanoformulations in Cancer Patents and Clinical Trials from the year 2000 to 2026, the majority of the electronic databases including Google Scholar, Embase, Web of Science, Scopus, and PubMed/MEDLINE were searched. The key benefits of nanoformulation lie in their ability to enhance the water solubility of drugs, thereby overcoming the limitations of traditional drug formulations. The nanoformulation facilitates efficiency and enhances therapeutic efficacy. The perfection portrayed by nanoformulation in carrying the therapeutics with better performance. This article provides comprehensive details on nanoformulation-based patents and clinical trials of various cancer conditions and draws attention to novel formulation of drugs that has been designed to target specific diseases. The article will likely discuss the outcomes of the clinical trials that evaluated the effectiveness of the formulations. The current nanoformulation-based therapies can be a potential source to address the unmet medical needs that advance the patient outcomes.